WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H559184
CAS#: 121809-82-3
Description: L 345 is a bioactive chemical.
Hodoodo Cat#: H559184
Name: L 345
CAS#: 121809-82-3
Chemical Formula: C17H15Cl3N2O4
Exact Mass: 416.01
Molecular Weight: 417.660
Elemental Analysis: C, 48.89; H, 3.62; Cl, 25.46; N, 6.71; O, 15.32
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: L 345; L-345; L345;
IUPAC/Chemical Name: 2-methyl-2-(4-(3-(3,4,5-trichlorophenyl)ureido)phenoxy)propanoic acid
InChi Key: RETXRBKBFDJBQS-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H15Cl3N2O4/c1-17(2,15(23)24)26-11-5-3-9(4-6-11)21-16(25)22-10-7-12(18)14(20)13(19)8-10/h3-8H,1-2H3,(H,23,24)(H2,21,22,25)
SMILES Code: CC(OC1=CC=C(NC(NC2=CC(Cl)=C(Cl)C(Cl)=C2)=O)C=C1)(C)C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 417.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Horjen AW, Seljeflot I, Berge T, Smith P, Arnesen H, Tveit A. Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation. Thromb J. 2017 Dec 28;15:30. doi: 10.1186/s12959-017-0153-1. eCollection 2017. PubMed PMID: 29299030; PubMed Central PMCID: PMC5745972.
2: Riddle MC. Diabetes: Controlling glucose levels in elderly people--benefits versus risks. Nat Rev Endocrinol. 2015 May;11(5):257-8. doi: 10.1038/nrendo.2015.23. Epub 2015 Feb 24. PubMed PMID: 25707784.
3: Bi XY, Zhao JJ, Yan T, Li C, Zhou HT, Huang Z, Zhao H, Cai JQ. [Peri-operative treatment for hepatocellular carcinoma patients complied with cirrhosis and hypersplenism]. Zhonghua Wai Ke Za Zhi. 2010 Oct 15;48(20):1539-41. Chinese. PubMed PMID: 21176666.
4: Riddle MC. Therapy: What evidence should guide the use of thiazolidinediones? Nat Rev Endocrinol. 2010 Nov;6(11):600-2. doi: 10.1038/nrendo.2010.156. PubMed PMID: 20962864.
5: Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010 Aug 24;122(8):844-6. doi: 10.1161/CIRCULATIONAHA.110.960138. PubMed PMID: 20733112; PubMed Central PMCID: PMC2980502.
6: Riddle MC. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. Diabetes Care. 2008 Feb;31 Suppl 2:S125-30. doi: 10.2337/dc08-s231. PubMed PMID: 18227472.
7: Riddle MC. Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary. J Clin Endocrinol Metab. 2008 Feb;93(2):372-4. Epub 2007 Dec 11. PubMed PMID: 18073293.
8: Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care. 1998 Jul;21(7):1052-7. PubMed PMID: 9653594.
9: Kister J, Griffon N, Henthorn JS, Marden MC, Poyart C, Papassotiriou I, Promé D, Galactéros F, Davies SC, Wajcman H. Alteration of an intersubunit contact in hemoglobin variants: comparative study of modifications at position alpha 126 Asp (H9). C R Acad Sci III. 1997 Nov;320(11):849-55. PubMed PMID: 9499936.
10: Dumoulin A, Kiger L, Jiang R, Baudin V, Vasseur C, Sligar SG, Marden MC, Pagnier J, Poyart C. Loss of allosteric behaviour in recombinant hemoglobin alpha 2 beta 2(92)(F8) His-->Ala: restoration upon addition of strong effectors. FEBS Lett. 1995 Oct 23;374(1):39-42. PubMed PMID: 7589508.
11: Yamamoto J, Ohyanagi M, Morita M, Iwasaki T. Beta-adrenoceptor-G protein-adenylate cyclase complex in rat hearts with ischemic heart failure produced by coronary artery ligation. J Mol Cell Cardiol. 1994 May;26(5):617-26. PubMed PMID: 8072016.
12: Lalezari I, Lalezari P, Poyart C, Marden M, Kister J, Bohn B, Fermi G, Perutz MF. New effectors of human hemoglobin: structure and function. Biochemistry. 1990 Feb 13;29(6):1515-23. PubMed PMID: 2334712.
13: Langner NR, Hasselback PD, Dunkley GC, Corber SJ. Attitudes and practices of primary care physicians in the management of elevated serum cholesterol levels. CMAJ. 1989 Jul 1;141(1):33-8. Erratum in: Can Med Assoc J 1989 Aug 15;141(4):278. PubMed PMID: 2731100; PubMed Central PMCID: PMC1269270.
